Search clinical trials for: BRAF Mutation-Related Tumors

Total 16087 results

Ikena Oncology

Recruiting

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

Colorectal Cancer | Pancreatic Cancer | Thyroid Carcinoma | Solid Tumor, Adult | Malignant Melanoma | Non-Small Cell Lung Carcinoma | BRAF Gene Mutation | Gliomas, Malignant | Ras (Kras or Nras) Gene Mutation | CRAF Gene Mutation

United States
Shandong University

Not yet recruiting

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Ameloblastoma
Immuneering Corporation

Recruiting

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors

Pancreas Adenocarcinoma | Non-small Cell Lung Cancer | Advanced Solid Tumor (Phase 1) | Malignant Melanoma (Cutaneous)

United States
National Cancer Center, Japan
Ono Pharmaceutical Co. Ltd

Recruiting

Binimetinib in Patients With BRAF Fusion-positive Low-grade Glioma or Pancreatic Cancer (Perfume) (Perfume)

Pancreatic Cancer | Low-grade Glioma

Japan
Regina Elena Cancer Institute

Recruiting

Versatile Ampification Single-Molecule Detection in Liquid Biopsy (VerSiLiB)

Melanoma (Skin) | Liquid Biopsy | Melanoma Stage IV | Melanoma Stage III | BRAF V600E

Italy
Pfizer
Merck Sharpe & Dohme LLC

Recruiting

A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma (PORTSIDE)

Melanoma

Italy, Spain, Czechia, Germany, Slovakia, Poland, United Kingdom
ABM Therapeutics Shanghai Company Limited

Recruiting

A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors

Primary Malignant Brain Tumor

China
Novartis Pharmaceuticals

Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors

United States
Black Diamond Therapeutics, Inc.

Recruiting

A Study of BDTX-4933 in Patients With KRAS, BRAF and Select RAS/MAPK Mutation-Positive Cancers

Melanoma | Colorectal Cancer | NSCLC | Solid Tumor | Metastatic Lung Cancer | Metastatic Lung Non-Small Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Histiocytosis | Melanoma (Skin) | Recurrent Melanoma | Thyroid Carcinoma | Thyroid Cancer | Brain Metastases | Recurrent Histiocytic and Dendritic... and other conditions

United States
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
Iovance Biotherapeutics, Inc.

Recruiting

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Melanoma | Metastatic Melanoma | Unresectable Melanoma

United States, Spain, Australia, France, Netherlands, Italy, Canada, Sweden
C4 Therapeutics, Inc.

Recruiting

A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors

Melanoma | NSCLC | Solid Tumors | CRC | ATC

United States, Spain, France
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors

Glioma | Melanoma | Colorectal Cancer | Brain Neoplasms | Non-Small Cell Lung Cancer | Thyroid Cancer | Malignant Neoplasms

Canada, United States
Eva Marie Erfurth, MD, PhD
Novartis

Recruiting

Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma (Swecranio)

Craniopharyngioma

Sweden
University Hospital, Montpellier

Recruiting

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

Metastatic Melanoma

France
ABM Therapeutics Shanghai Company Limited

Recruiting

A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors

Advanced Solid Tumor | BRAF V600 Mutation

China
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Central Nervous System

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.

Glioma | Melanoma | Thyroid Cancer | Non-Small-Cell Lung Cancer

United States, Canada, Israel
Dr. Ronnie Shapira

Not yet recruiting

Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma (MK3475-C01)

Metastatic Melanoma | Malignant Melanoma | Immunotherapy | Malignant Melanoma Stage IV | BRAF V600E
Shanghai Kechow Pharma, Inc.

Recruiting

HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation

Melanoma

China
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation

Advanced Melanoma

China
CCTU- Cancer Theme
Pierre Fabre Medicament

Not yet recruiting

Perioperative Encobini in BRAFV600 Mutant Stage III (B/C/D) or Oligometastatic Stage IV Melanoma (PREMIUM)

Melanoma | Cancer

United Kingdom
Shanghai Henlius Biotech

Recruiting

The Efficacy of HLX208 (BRAF V600E Inhibitor) for Refractory Primary Brain Tumors With BRAF Mutation After First-line Treatment

Brain Tumor, Primary

China
M.D. Anderson Cancer Center

Recruiting

Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Day One Biopharmaceuticals, Inc.

Recruiting

Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors

Melanoma | Colorectal Cancer | Solid Tumor | Non Small Cell Lung Cancer | Bladder Cancer | Thyroid Cancer, Papillary | Pilocytic Astrocytoma | Bladder Urothelial Carcinoma | Non-Small Cell Adenocarcinoma | MEK Mutation | RAS Mutation | Pancreatic Acinar Carcinoma | RAF Mutation | CRAF Gene Amplification | RAF1 Gene Amplification and other conditions

United States, Canada, Korea, Republic of, Spain, Australia, Belgium, France
Shanghai Henlius Biotech

Recruiting

HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors

Solid Tumor

China
Novartis Pharmaceuticals

Recruiting

Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma. (LEAD Melanoma)

Melanoma

Turkey
Pierre Fabre Medicament

Recruiting

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

Melanoma | Non-small Cell Lung Cancer | Solid Tumor, Adult

United States, Australia, France, Spain, Taiwan, Korea, Republic of, China, Netherlands
Pierre Fabre Medicament

Recruiting

A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients (TavieSkin)

Metastatic Melanoma | Melanoma (Skin) | BRAF V600 Mutation

Portugal
Jill M Kolesar
National Cancer Institute (NCI); Novartis

Recruiting

Nilotinib Plus Dabrafenib/Trametinib in Metastatic Melanoma

Metastatic Melanoma | BRAF Gene Mutation

United States
H. Lee Moffitt Cancer Center and Research Institute
Pfizer

Recruiting

Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma

Melanoma Stage IV | BRAF V600 Mutation | Melanoma Stage III

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATE (CELEBRATE)

Melanoma | Metastasis

Australia
Novartis Pharmaceuticals

Recruiting

Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection

Melanoma

China
Hoffmann-La Roche

Recruiting

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

Solid Tumors

Belgium, United States, Australia, Canada, Japan, Korea, Republic of, United Kingdom, Germany, Taiwan, China, Puerto Rico, Israel, Singapore, Spain, Brazil, Portugal, South Africa, Denmark, France, Italy, Poland, Hong Kong, New Zealand and more
Peking University
Hangzhou DIAN Medical Diagnostic Center Co., Ltd., China

Recruiting

Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics (VISIONARY)

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Gastrointestinal Stromal Tumors | Neuroendocrine Tumors | Esophageal Squamous Cell Carcinoma | Biliary Tract Neoplasms | Unknown Primary Cancer | Digestive Cancer

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb; Array BioPharma

Recruiting

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous... and other conditions

United States
MapKure, LLC

Recruiting

Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors

Solid Tumor | B-Raf Mutation-Related Tumors

United States, Australia
Memorial Sloan Kettering Cancer Center

Recruiting

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

Thyroid Cancer | Anaplastic Thyroid Cancer | BRAF Gene Mutation | BRAF Mutation-Related Tumors

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI); American Lebanese Syrian Associated Charities...

Recruiting

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Low Grade Glioma (LGG) of Brain With BRAF Aberration | High Grade Glioma (HGG) of the Brain With BRAF Aberration | Low Grade Glioma of Brain With Neurofibromatosis Type 1

United States
Hospices Civils de Lyon

Recruiting

Interest of Tumor Replicates in Avian Embryo to Model Therapeutic Effects of BRAFi/MEKi in BRAF Mutated Melanoma (MELANOPREDICT)

Melanoma

France
Universitair Ziekenhuis Brussel
University Hospital, Ghent

Recruiting

Dabrafenib/Trametinib/Hydroxychloroquine for Advanced Pretreated BRAF V600 Mutant Melanoma (COMBI-R2)

Melanoma

Belgium
Inge Marie Svane

Recruiting

Melanoma Metastasized to the Brain and Steroids (MEMBRAINS)

Malignant Melanoma

Denmark
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Pathologic Stage III Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIA Cutaneous Melanoma...

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma

Skin Cancer | Melanoma (Skin) | Skin Carcinoma | Skin Melanoma

United States
Novartis Pharmaceuticals

Recruiting

Dabrafenib and/or Trametinib Rollover Study

Melanoma | Solid Tumor | High Grade Glioma | Non Small Cell Lung Cancer | Rare Cancers

Spain, Germany, United States, Argentina, Austria, Denmark, France, Hungary, Netherlands, China, Japan, Thailand
National Cancer Institute (NCI)

Recruiting

Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)

Malignant Glioma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Recurrent Ependymoma | Recurrent Ewing Sarcoma | Recurrent Hepatoblastoma | Recurrent Langerhans Cell Histiocytosis | Recurrent Malignant Germ Cell Tumor | Recurrent Malignant Solid Neoplasm | Recurrent... and other conditions

United States, Puerto Rico, Australia, Canada
Curegenix Inc.
Merck Sharp & Dohme LLC

Recruiting

CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)

Solid Tumors | GI Cancer

United States, Taiwan
Melanoma Institute Australia
Novartis

Recruiting

Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma (MatchMel)

Melanoma

Australia
University of Louisville
James Graham Brown Cancer Center

Recruiting

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

Melanoma

United States

Search clinical trials for: BRAF Mutation-Related Tumors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations